Does Creatine Raise DHT? What the Human Evidence Actually Shows

The short answer: does creatine increase DHT?

Current human evidence does not establish that creatine consistently increases circulating dihydrotestosterone (DHT). A small 2009 randomized study in college-aged male rugby players reported a temporary DHT increase during a creatine loading-and-maintenance protocol. A later 12-week randomized placebo-controlled trial found no creatine-specific change in DHT or related hormone measures.

The newer trial also assessed objective hair outcomes and found no significant differences between the creatine and placebo groups. That provides more direct evidence than the earlier study, but it does not prove that creatine can never affect DHT or hair-related biology in any individual, dose pattern, or timeframe. The available research remains limited in population and duration.

The question matters because DHT is involved in androgen signaling, which is relevant to androgenetic alopecia in susceptible hair follicles. But a change in blood DHT is not the same as demonstrated follicle miniaturization or clinical hair loss.

Why DHT is associated with hair-loss concerns

DHT is produced from testosterone through the action of the enzyme 5-alpha-reductase. It binds strongly to androgen receptors and participates in androgen signaling. In people with androgen-sensitive follicles, this signaling is relevant to androgenetic alopecia.

That biological connection does not establish that creatine raises DHT or causes hair loss. It also does not mean that every type of shedding is driven by DHT. Hair loss can involve different biological processes, and the presence or absence of a change in serum DHT does not by itself identify the cause of a person's hair changes.

The key distinction is between a hormone measurement and a clinical outcome. Serum DHT reflects the amount measured in the bloodstream at the time of testing. Follicles may differ in their sensitivity to androgen signaling, and serum DHT cannot be treated as interchangeable with androgen activity inside scalp tissue. Actual hair loss requires assessment of the hair and follicles themselves, not just an inference from a blood hormone result.

The 2009 rugby-player study that started the debate

The study that triggered much of the creatine-and-hair-loss debate was a small randomized, placebo-controlled crossover trial involving 20 college-aged male rugby players. During the creatine condition, participants took 25 grams per day with glucose for seven days, followed by 5 grams per day with glucose for another 14 days.

Serum DHT rose by 56% from baseline after the loading phase and remained 40% above baseline after the maintenance phase. The DHT-to-testosterone ratio also increased, while testosterone itself did not significantly change. The reported DHT values remained within the reference range stated by the study.

Those findings suggested a short-term change in circulating DHT under that specific protocol. They did not show that participants lost hair. The researchers did not measure shedding, hair density, follicle miniaturization, baldness progression, or other direct hair outcomes.

This is the central inferential gap. A hormone result can generate a biological hypothesis, but it does not demonstrate a clinical effect. The study was also small, involved a specific group of young male athletes, and covered only three weeks. Its findings therefore cannot establish that creatine causes hair loss or that the same DHT response occurs with every creatine regimen.

What the 2025 randomized trial found

A 2025 double-blind, randomized, placebo-controlled trial compared creatine monohydrate with a maltodextrin placebo for 12 weeks. The participants were resistance-trained men aged 18 to 40, and 38 participants completed the trial. The creatine regimen used in the study was 5 grams per day.

Unlike the 2009 study, this trial measured both circulating hormone markers and objective hair outcomes. It found no significant creatine-specific changes in serum DHT, the DHT-to-testosterone ratio, total testosterone, or free testosterone.

The researchers also found no significant differences in the assessed hair measures. These included hair count, density, the proportions of hairs in different growth phases, follicular-unit count, terminal and vellus hair proportions, and cumulative hair thickness. The study did not find evidence that the tested creatine regimen changed either the measured DHT markers or the measured hair parameters over the study period.

The results are reassuring for the population, dose, duration, and outcomes studied. They are not definitive evidence of lifelong hair safety, and they do not answer whether the results apply to women, adolescents, people with a strong genetic predisposition to hair loss, higher-dose patterns, loading phases, or longer use.

How strong is the evidence, and what remains unknown?

The evidence is better assessed by study design and relevance than by simply counting studies. The 2009 trial was randomized but small and short, and it measured circulating hormones without measuring hair. Its DHT finding was therefore a signal that required further investigation, not evidence that participants developed hair loss.

The 2025 trial addressed the main missing outcome by measuring both DHT-related markers and objective hair parameters. It found no creatine-specific changes in either category over 12 weeks. This makes the newer study more directly relevant to the hair-loss question, although it was still relatively small and limited in duration.

Important evidence gaps remain. The 2025 trial did not record participants' family histories of hair loss, evaluate women, measure androgen activity within scalp tissue, or test longer exposure or higher-dose regimens. These limitations mean that its results should not be generalized beyond the studied population, regimen, timeframe, and measurements.

The narrow conclusion is that the best direct evidence is reassuring for resistance-trained men using the studied regimen over the studied period. It does not establish that every possible long-term effect, individual response, or supplement pattern has been excluded.

Practical next steps if you use creatine and notice hair loss

If shedding begins after starting creatine, timing alone does not prove that creatine caused it. Hair changes can have explanations unrelated to a supplement, and the available trials do not establish that stopping creatine will reverse shedding.

Document when the hair change began, any changes in supplements or other relevant routines, and whether the pattern appears diffuse, patchy, or concentrated in particular areas. This record can help a qualified healthcare professional assess the situation without relying only on memory.

Seek medical or dermatologic assessment if hair loss is sudden, patchy, persistent, progressive, or distressing. A clinician can evaluate the pattern and determine whether further assessment is appropriate. There is no need to treat a perceived association as a confirmed diagnosis.

Whether to continue or pause creatine is an individualized decision that can be discussed with a qualified healthcare professional, particularly when the hair loss is ongoing or concerning. The current evidence does not support assuming either that creatine is responsible or that stopping it will reliably restore hair.